| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We attempted to develop a collagen-based bone formation system using a fusion protein (collagen binding-bFGF, CB-bFGF) consisting of bFGF and the collagen-binding domain (CBD) of Clostridium histolyticum collagenase. The affinity of the fusion protein towards collagen and demineralized bone powder (DBP) was confirmed by collagen-binding assays. Moreover, the combination of the collagen binding-bFGF fusion protein (CB-bFGF) with collagen powder or DBP induced bone formation at protein concentrations lower than those required for bFGF alone in mice fracture models. Therefore, because of the potential adverse effects of bFGF, particularly when administered at high doses, the use of CP/CB-bFGF composite may be a safer alternative for bone repair by limiting bFGF exposure at fracture sites. Taken together, these properties suggest that the CB-bFGF/collagen powder composite is a promising injectable material for fracture healing in the clinical setting.
|
